Viridian Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2026 Annual Meeting of Stockholders held by Viridian Therapeutics, Inc. on June 2, 2026. The meeting was attended by holders of common stock as of the record date of April 7, 2026, with 103,071,889 shares issued and outstanding at that time.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
All proposals presented at the Annual Meeting were approved, and all director nominees were elected. The specific voting outcomes were:
- Election of Directors: Both Class II nominees, Tomas Kiselak and Jennifer K. Moses, were elected to serve until the 2029 Annual Meeting.
- Independent Auditor: The selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.
- Executive Compensation (Say-on-Pay): The advisory vote on the compensation of named executive officers was approved.
- Frequency of Say-on-Pay Vote: Stockholders voted to conduct the advisory vote on executive compensation annually (1 Year).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the results of the shareholder vote.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (103,071,889) against the most recent 10-K or 10-Q filings to confirm capital structure changes.
- Confirm the tenure of the newly elected directors (Tomas Kiselak and Jennifer K. Moses) through the 2029 Annual Meeting.
- Note the shareholder preference for an annual advisory vote on executive compensation.
- Review the full proxy statement for detailed breakdowns of "Withheld" votes and "Broker Non-Votes" which may indicate shareholder sentiment nuances.